Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly Reuters Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar Novo Nordisk's CagriSema Falls Short in Head to Head Trial vs Zepbound Bryce Platt, PharmD posted on the topic LinkedIn CagriSema vs Tirzepatide: Weight Loss Results in REDEFINE 4 Trial Paramesh Shamanna posted on the topic LinkedIn New in the August 14, 2025, issue of NEJM: CagrilintideSemaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) CagrilintideSemaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial)